Anadys’ Hepatitis C Drug Shows Promise-:-ANA773 Demonstrates Significant Antiviral Response in Early Trial

[Guest guest]

Anadys’ Hepatitis C Drug Shows Promise

Anadys Pharmaceuticals Inc.’s experimental oral hepatitis C drug has shown promise in an early phase studies, which means it could potentially replace injectable interferon drugs used to treat the disease.

Read More:

http://www.visitbulgaria.info/11004-anadys-hepatitis-c-drug-shows-promise

http://tinyurl.com/qu8fdy

ANA773 Demonstrates Significant Antiviral Response in Early Trial

11 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS) today announced viral load data for the final cohort of hepatitis C patients in a Phase I clinical trial of ANA773, the Company's oral inducer of endogenous ...

Read More:

http://www.drugs.com/clinical_trials/ana773-demonstrates-significant-antiviral-response-early-clinical-trial-hepatitis-c-patients-7906.html

http://tinyurl.com/pd68av